Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in patients with chronic hepatitis B with immune-tolerant phase.
APA
Tseng TC, Kao JH (2026). Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in patients with chronic hepatitis B with immune-tolerant phase.. Hepatology (Baltimore, Md.), 83(1), E8-E9. https://doi.org/10.1097/HEP.0000000000001366
MLA
Tseng TC, et al.. "Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in patients with chronic hepatitis B with immune-tolerant phase.." Hepatology (Baltimore, Md.), vol. 83, no. 1, 2026, pp. E8-E9.
PMID
40258074
같은 제1저자의 인용 많은 논문 (5)
- Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis.
- Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification.
- Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients.
- Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B.
- Reply to: 'Rethinking "inactive chronic hepatitis B": should we treat patients with high HBsAg levels?'.